

**Lung Cancer Research
Advocate Lutheran General Hospital**

For more information about the following research studies, please contact the Advocate Lutheran General Lung Cancer Research Coordinator, Kathy Tolzien. Her phone number is 847-268-8569.

Neoadjuvant therapy for NSCLC Principle Investigator – Dr Daniel Milton
"RTOG 0412/ SWOG S0332: A phase III randomized trial of preoperative chemotherapy versus preoperative concurrent chemotherapy and thoracic radiotherapy followed by surgical resection and consolidation chemotherapy in favorable prognosis patients with stage IIIA (N2) Non-Small Cell Lung Cancer"

Adjuvant therapy for NSCLC Principle Investigator – Dr Daniel Milton
"RTOG-0214: a phase III comparison of prophylactic cranial radiation versus observation in patients with locally advanced NSCLC"

Primary therapy for metastatic NSCLC Principle Investigator – Dr Daniel Milton
"Phase II study evaluating the safety and efficacy of oxaliplatin and docetaxel as first-line therapy in stage IV or IIIB unresectable NSCLC"

Maintenance therapy for metastatic NSCLC Principle Investigator – Dr Daniel Milton
'A phase III double-blind, placebo-controlled study of maintenance pemetrexed plus BSC versus BSC immediately following "induction treatment" for advanced NSCLC'

Second-line therapy for metastatic NSCLC Principle Investigator – Dr Daniel Milton
"Phase II study of the anti-angiogenesis agent AG-013736 as second-line treatment in patients with advanced NSCLC"